[{"address1": "60 Jubilee Avenue", "address2": "Milton Park", "city": "Abingdon", "zip": "OX14 4RX", "country": "United Kingdom", "phone": "44 12 3543 0000", "website": "https://www.adaptimmune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.", "fullTimeEmployees": 506, "companyOfficers": [{"maxAge": 1, "name": "Mr. Adrian G.  Rawcliffe", "age": 52, "title": "CEO & Director", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 1043255, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William C. A. Bertrand Jr., Esq., J.D.", "age": 59, "title": "COO & Chief Compliance Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 703097, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Helen Katrina Tayton-Martin MBA, Ph.D.", "age": 57, "title": "Co-Founder", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 677404, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher James Hill ACA, BA (Hons)", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juli P. Miller Ph.D.", "title": "VP of Corporate Affairs & Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kerry  Sharp", "title": "Senior VP & General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Dana  Lynch", "title": "Senior Director of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Margaret  Henry", "title": "Corporate Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kimberly  Freeman", "title": "Vice President of Commercial Planning", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Laura  Gunn", "title": "Vice President of Medical Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.127, "open": 0.133, "dayLow": 0.133, "dayHigh": 0.162, "regularMarketPreviousClose": 0.127, "regularMarketOpen": 0.133, "regularMarketDayLow": 0.133, "regularMarketDayHigh": 0.162, "payoutRatio": 0.0, "beta": 2.241, "forwardPE": -0.3868421, "volume": 80047398, "regularMarketVolume": 80047398, "averageVolume": 75981765, "averageVolume10days": 242253710, "averageDailyVolume10Day": 242253710, "bid": 0.038, "ask": 0.198, "bidSize": 1, "askSize": 1, "marketCap": 38962584, "fiftyTwoWeekLow": 0.04, "fiftyTwoWeekHigh": 1.0, "allTimeHigh": 21.57, "allTimeLow": 0.04, "priceToSalesTrailing12Months": 0.5986415, "fiftyDayAverage": 0.10758, "twoHundredDayAverage": 0.32826, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 256394496, "profitMargins": -2.6082199, "floatShares": 1185257705, "sharesOutstanding": 265051591, "sharesShort": 23052335, "sharesShortPriorMonth": 11073333, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.087, "heldPercentInsiders": 0.0063099996, "heldPercentInstitutions": 0.31320998, "shortRatio": 0.36, "shortPercentOfFloat": 0.105299994, "impliedSharesOutstanding": 226172000, "bookValue": -0.268, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -169756000, "trailingEps": -0.66, "forwardEps": -0.38, "enterpriseToRevenue": 3.939, "enterpriseToEbitda": -1.868, "52WeekChange": -0.8452631, "SandP52WeekChange": 0.1529237, "quoteType": "EQUITY", "currentPrice": 0.147, "targetHighPrice": 1.5, "targetLowPrice": 0.09, "targetMeanPrice": 0.68333, "targetMedianPrice": 0.46, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 26061000, "totalCashPerShare": 0.016, "ebitda": -137240992, "totalDebt": 48680000, "quickRatio": 1.067, "currentRatio": 1.516, "totalRevenue": 65085000, "revenuePerShare": 0.252, "returnOnAssets": -0.40862998, "returnOnEquity": -13.410971, "grossProfits": -63606000, "freeCashflow": -123189752, "operatingCashflow": -190027008, "revenueGrowth": -0.893, "grossMargins": -0.97727996, "ebitdaMargins": -2.10864, "operatingMargins": -2.21452, "financialCurrency": "USD", "symbol": "ADAP", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1758931194, "regularMarketTime": 1758916801, "exchange": "NCM", "messageBoardId": "finmb_113495056", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "fiftyTwoWeekLowChangePercent": 2.6750002, "fiftyTwoWeekRange": "0.04 - 1.0", "fiftyTwoWeekHighChange": -0.853, "fiftyTwoWeekHighChangePercent": -0.853, "fiftyTwoWeekChangePercent": -84.52631, "dividendDate": 1522368000, "earningsTimestamp": 1755144000, "earningsTimestampStart": 1762950600, "earningsTimestampEnd": 1762950600, "earningsCallTimestampStart": 1742472000, "earningsCallTimestampEnd": 1742472000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.66, "epsForward": -0.38, "epsCurrentYear": -0.471, "priceEpsCurrentYear": -0.31210193, "fiftyDayAverageChange": 0.03942, "fiftyDayAverageChangePercent": 0.366425, "twoHundredDayAverageChange": -0.18126, "twoHundredDayAverageChangePercent": -0.5521842, "priceToBook": -0.54850745, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "regularMarketChangePercent": 15.748, "regularMarketPrice": 0.147, "shortName": "Adaptimmune Therapeutics plc", "longName": "Adaptimmune Therapeutics plc", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1430919000000, "postMarketChangePercent": -0.4761884, "postMarketPrice": 0.1463, "postMarketChange": -0.00069999695, "regularMarketChange": 0.02, "regularMarketDayRange": "0.133 - 0.162", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 75981765, "fiftyTwoWeekLowChange": 0.107, "displayName": "Adaptimmune Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-09-27"}]